Vemurafenib Delayed Progression in Metastatic, BRAF-Mutant CRC

Video
Conference|ASCO Gastrointestinal Cancer Symposium

This video covers results of the SWOG 1406 study, which tested the BRAF inhibitor vemurafenib in combination with irinotecan and cetuximab for patients with metastatic, BRAF-mutant colorectal cancer.

Scott Kopetz, MD, on Vemurafenib in Metastatic, BRAF-Mutant CRC
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Scott Kopetz, MD, of the University of Texas MD Anderson Cancer Center in Houston, discusses results of the SWOG 1406 study, which tested the BRAF inhibitor vemurafenib in combination with irinotecan and cetuximab for patients with metastatic, BRAF-mutant colorectal cancer.

      Dr. Kopetz presented results of the study (abstract 520) at the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held January 19–21 in San Francisco.

      Recent Videos
      Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
      Novel Treatments May Have the Potential to Impact GI Cancer Care
      Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
      Making a ‘World of Difference’ Via Multidisciplinary Care in GI, GU Cancers
      Staged Colectomy May Be Preferable to Upfront Colectomy in Appendix Cancer
      Staged Colectomy May Be Preferable to Upfront Colectomy in Appendix Cancer
      Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
      CRC Yields Most Prevalent Data at Recent GI Meeting
      No Subgroups Benefit From HIPEC/CRS in Colorectal Peritoneal Metastasis
      No Subgroups Benefit From HIPEC/CRS in Colorectal Peritoneal Metastasis
      HIPEC/CRS Confers No Benefit, Adds Risk in Colorectal Peritoneal Metastases
      HIPEC/CRS Confers No Benefit, Adds Risk in Colorectal Peritoneal Metastases
      Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
      Ensuring Ancillary Care Access to Bolster QOL in Pancreatic Cancer
      Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
      PIPAC-MMC Shows Efficacy in Multiple Response Criteria for Peritoneal Mets
      Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
      Peritoneal Tumor Treatment Enhanced by Pre-PIPAC-MMC Small Incision Surgery
      Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
      Intraperitoneal Therapy Seeks to Address “Nihilism” Around Peritoneal Mets
      Related Content
      Postoperative complications and mortality after standard or postponed surgery for esophageal cancer after active surveillance were similar in both groups.

      Active Surveillance Shows Noninferior OS vs Surgery in Esophageal Cancer

      Roman Fabbricatore
      April 5th 2025
      Article

      Postoperative complications and mortality after standard or postponed surgery for esophageal cancer after active surveillance were similar in both groups.

      The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

      Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

      Marwan G. Fakih, MD
      February 24th 2025
      Podcast

      The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

      A Staged Approach Offers Benefits Without OS Detriment in Appendix Cancers

      A Staged Approach Offers Benefits Without OS Detriment in Appendix Cancers

      Tim Cortese
      April 2nd 2025
      Article

      Muhammad Talwa Waheed, MD, found that resection after appendectomy should be prioritized in the treatment of patients with appendiceal cancer.

      Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

      Educating Patients and Clinicians on End-of-Life Care and Discussions

      Kelley A. Rone, DNP, RN, AGNP-c
      November 11th 2024
      Podcast

      Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

      Local Excision After Chemo Achieves Negative Margins in Rectal Cancer

      Local Excision After Chemo Achieves Negative Margins in Rectal Cancer

      Tim Cortese
      March 31st 2025
      Article

      A phase 2 trial presented at SSO met its primary end point by achieving negative margins in 79% of patients with node-negative rectal cancer.

      Sirexatamab plus bevacizumab/chemotherapy significantly improved overall response rate in patients with high DKK1 levels in the phase 2 DeFianCe study.

      Sirexatamab Combo Shows Positive Activity in Advanced MSS Colorectal Cancer

      Russ Conroy
      March 31st 2025
      Article

      Sirexatamab plus bevacizumab/chemotherapy significantly improved overall response rate in patients with high DKK1 levels in the phase 2 DeFianCe study.